SCHEMBL834523

SCHEMBL834523

CN(C)c1ccc(N2Cc3cccc(C#N)c3C2=O)cc1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PARP1 P09874 5/20 0.61
HTR2C P28335 2/20 0.47
POLB P06746 4/20 0.42
TDP1 Q9NUW8 3/20 0.42
ESR1 P03372 2/20 0.42
APEX1 P27695 2/20 0.42
RECQL P46063 2/20 0.42
BLM P54132 2/20 0.42
MCL1 Q07820 2/20 0.42
ESR2 Q92731 2/20 0.42
HSD17B10 Q99714 2/20 0.42
KDM4E B2RXH2 1/20 0.42
NR4A1 P22736 1/20 0.42
PTPN7 P35236 1/20 0.42
GAA P10253 1/20 0.40
HTR2A P28223 1/20 0.39
HTR2B P41595 1/20 0.39
NPC1 O15118 6/20 0.39
RAB9A P51151 6/20 0.39
PKM P14618 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL834078 0.82 PARP1 (0.63) PARP1HTR2CPOLBTDP1ESR1
SCHEMBL835994 0.81 PARP1 (0.49) PARP1HTR2CPOLBTDP1ESR1
SCHEMBL10113636 0.77 TP53 (0.62) PARP1HTR2CPOLBTDP1ESR1
SCHEMBL834080 0.77 PARP1 (0.65) PARP1HTR2CPOLBTDP1ESR1
SCHEMBL835374 0.76 PARP1 (1.00) PARP1POLBTDP1ESR1APEX1
SCHEMBL4258304 0.74 NPC1 (0.69) PARP1HTR2CKDM4EGAANPC1
SCHEMBL17519983 0.73 PARP1 (0.53) PARP1HTR2CHSD17B10KDM4EGAA
SCHEMBL10113584 0.72 TP53 (0.45) PARP1HTR2CPOLBTDP1ESR1
SCHEMBL24761864 0.70 HTR2C (0.47) PARP1HTR2CMCL1KDM4EHTR2A
SCHEMBL835113 0.70 PARP1 (0.67) PARP1HTR2CTDP1HTR2AHTR2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8143284-B2 2-cyclohexyl-3-oxo-2,3-dihydro-1H-isoindole-4-carboxamide; allergic encephalitis, arthritis, cardiac and kidney toxicities from doxorubicin-based and platinum-based antineoplastic agents, carcinoma of the breast, central nervous system inflammation, cervical carcinoma, ABBOTT LABORATORIES (US) 2012-03-27 US disclosed
US-20080108659-A1 POLY(ADP-RIBOSE)POLYMERASE INHIBITORS ABBVIE INC. 2008-05-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080108659-A1 POLY(ADP-RIBOSE)POLYMERASE INHIBITORS PARP1, PARP11, PARP2 PARP1 1/4885HTR2C 4265/4885POLB 20/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.